hep b cure gilead. As part of the clinical collaboration, the companies are expecting to launch a Phase II trial evaluating combination therapies for both treatment-experienced. -- Data on Investigational TLR8 Agonist GS-9688 Support Continued Advancement of the Company’s HBV Cure Research Program --. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) . The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. The primary outcome of the study will be the proportion of patients. Home >; Treating Chronic Hep B . 8, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data on Vemlidy ® (tenofovir alafenamide 25 mg, TAF) that continue to support an improved safety profile compared with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (HBV) infection. First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research -- Gilead Sciences, Inc. Hepatitis B virus (Institute for Molecular Virology - University of Wisconsin–Madison) Gilead Sciences and trendy biotech Vir Biotechnology are teaming up in the effort to find a cure to the liver. Gilead's price gouging for sofosbuvir blocks millions of people from getting treatment. The first is GS-9688 which is a toll like receptor 8 agonist. Background & aims: One strategy to treat chronic hepatitis B virus (HBV) . Patricia Mendez Head HBV/HDV Cure at Gilead Sciences Basking Ridge, New Jersey, United States 500+ connections. However, the most important contender in hep B therapeutic vaccines is Gilead itself, with GS-4774, a project licensed from Globeimmune and in phase II in treatment-naive patients. The company’s biggest problem. Vitamin B supplements are available in many forms. Gilead Submits Biologics License Application to U. In December, Gilead closed out a year-long spending spree on cancer drugs by closing a deal much closer to their roots: a $1. Precision Biosciences' two-year collaboration with Gilead Sciences to develop new therapies to cure hepatitis B will end in September. Now that Gilead has introduced a "cure" for hepatitis C, researchers at the company are working on developing cures for HIV and hepatitis B, . Gilead Sciences will use Precision BioScience's ARCUS genome editing platform While current HBV treatments—including Gilead's Hepsera® . Worldwide 880,000 humans die each year from the consequences of an HBV . "This is an excellent application for our technology, which has. The Cure for Gilead Gilead has the cure for Hepatitis C (HCV) known as Sofosbuvir, which is taken alone or in combination with other drugs. Chronic hepatitis B (CHB) is an important cause of liver-related morbidity and mortality, increasing the risk of cirrhosis, liver failure, and liver cancer (hepatocellular carcinoma, HCC) . Learn about the benefits of vitamin B supplements and why you should take them for better health. regulators for all forms of the viral disease, making it the first treatment with such a comprehensive label. ’s hepatitis C drug was approved by U. Executive Director, Program Strategy Leadership (HBV Cure) Gilead Sciences United States 5 days ago Be among the first 25 applicants. Gilead has two drugs currently in phase I trials as new therapeutic compounds for the treatment of chronic HBV. In 2006, FDA approved HBV therapy Tyzeka to be taken for one year or longer. Despite global outrage at the cost of its Hepatitis C cure, Gilead reaps huge profits – aided by Australian taxpayer subsidies. BACK TO MAIN MENU Company Statements Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead to Expand Footprint in Oceanside Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Announces Actions to Remove Counterfeit HIV. In January, Gilead and Vir Biotechnology Inc. As I was reading the latest PK-PD study by Gilead on its lead experimental chronic HepB drug candidate GS-9620 (Fosdick et al. Most people infected with serious liver infection caused by hepatitis B virus are unaware they have it, yet early diagnosis and treatment . Research Scientist - HBV Cure United States - California - Foster City Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to the U. Executive Director, Program Strategy Leadership (HBV Cure) Gilead Sciences Foster City, CA 1 minute ago Be among the first 25 applicants. Current treatments suppress HBV replication, but they don’t completely clear up the infection. Harnessing the Power of RNAi Gene Silencing in a Quest of a Cure for Chronic Hepatitis B, and the HBV KnockDown blog written by Dirk Haussecker, who believes it's about time everyone got serious about a functional cure for hepatitis B. 28 August 2020: Progress towards finding a cure for chronic hepatitis B virus (HBV) infection was showcased at this year's Digital International Liver Congress™ (DILC). we delivered four curative treatments for chronic hepatitis C virus in less . The companies initiated a Phase II trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. Gilead is actively pursuing multiple research approaches with the goal of identifying a functional cure for patients with chronic HBV infection. “Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection,” said John McHutchison, MD, Chief Scientific Officer. Similar to Hepsera, Tyzeka is considered a second-line treatment . “The doctors in my town said, ‘You don’t have to worry about it, it’s just a virus,’” she recalls. Gilead Sciences will license generic version of Sovaldi for developing "It makes huge cost sense to treat and cure hepatitis C. Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting Jan. The country’s large population, coupled with a relatively high prevalence of chronic hepatitis B (HBV) and chronic hepatitis C (HCV), led to significant morbidity and mortality. Over the coming weeks and months, we will be implementing a phased approach to bringing employees back to site to ensure. Hepatitis B Developers Try To Repeat Gilead's Hep C Trick. a costly breakthrough to millions of hepatitis C sufferers thinks Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure. Can Gilead Develop a Cure for HIV?. Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019. announced a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus. Growing up in Nigeria offered Anu Osinusi her first glimpse of the devastating effects viral hepatitis can have on people’s lives. priced its highly effective hepatitis C drug Sovaldi (sofosbuvir) at $84,000 per treatment course. A Senate report says drug maker Gilead was looking to its bottom line when it Gilead's $1,000-a-pill Sovaldi, which can cure hepatitis, . The Foster City drugmaker is one of several companies trying to eradicate the blood-borne illness, which afflicts 3. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta. In China, Gilead recently announced the market launch of sofosbuvir at a prohibitive price of US$8,937 per treatment course, or around $100 per pill. (Nasdaq: GILD) today announced a licensing agreement to commercialise Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. 2013), it finally dawned on me. More than 257 million people, or 3. 05 IU/mL, is a rare event in the natural history of CHB that is associated with a reduced risk of HCC [10,11]. Gilead Sciences is turning to gene editing in its effort to develop a cure for hepatitis B virus infections—DNA-cutting enzymes that would eliminate the virus in the body, something current hep. Gilead Sciences introduced the first such drug to the U. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Findings from the Phase 3 study support the safety and efficacy profile of bulevirtide 2 mg once daily and are being presented today as a late-breaker in the International Liver Congress ™ (ILC) 2021 Official Press Program. Gilead's Asegua Therapeutics selected to partner with health department for to offer a hepatitis C cure to our most vulnerable patients. Developed by Gilead Sciences, Vemlidy (tenofovir alafenamide) is (NMPA) approved the drug to treat chronic HBV infection in adults and . 12, 2016-- Gilead Sciences, Inc. “This is an excellent application for our technology, which has. Gilead Sciences is the only company that has a solid presence in HBV with its brands Viread (tenofovir disoproxil fumarate, TDF) and Vemlidy ( . Gilead targets hep B in half a billion dollar deal with. (GILD) , VIR GILD , VIR By: SA News Team 17 Comments. Debate over about 'how to price a cure' entered the pharma industry lexicon when Gilead Sciences Inc. Gilead has the cure for Hepatitis C (HCV) known as Sofosbuvir, which is taken alone or in combination with other drugs. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy® (tenofovir alafenamide fumarate, TAF). “Unlike long-term or indefinite treatments for other chronic diseases, Harvoni offers a cure at a price that will significantly reduce hepatitis . and HBV who discontinue GENVOYA should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. 8 billion, which could have treated everyone while still earning . VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. er's fees from Gilead Sciences, Bristol Myers Squibb, AbbVie, and Novartis. When Silvana Lesidrenska learned she had chronic hepatitis B virus (HBV) in 2006, she wasn’t given much information by the doctors who diagnosed her. Compounds in Development for Chronic Hepatitis B ; Viread (Tenofovir) *Generics available, Inhibits viral DNA polymerase, Gilead Sciences ; Vemlidy (TAF or . to raise the price floor for all future hepatitis C treatments, . (GILD) and Vir Biotechnology, Inc. Gilead is presenting data on GS-9688, an investigational, oral selective toll-like receptor 8 (TLR8) agonist, one of several compounds under investigation as part of Gilead’s HBV cure program. January 12, 2021 - Gilead Sciences and Vir Biotechnology, Inc. "It's our largest program in virology by far," says John McHutchison, a gastroenterologist who is the company's chief scientific officer—and keeps a. A cure for hepatitis B has been elusive, but hepatitis C patients are being cured by Gilead Sciences' Sovaldi and Harvoni by the hundreds of thousands of patients annually. I will discuss why HBV if so difficult to find a cure for and why the current drugs. By Rory Carroll and Andrew Chung SAN JOSE (Reuters) - Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. Gilead Sciences hiring Director Clinical Development HBV Cure. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s HIV franchise brought in more than $14 billion in revenue last year. Our interview process may be conducted virtually and some roles will be asked to temporarily work from home. Hepatitis B Cure Research Gilead is presenting data on GS-9688, an investigational, oral selective toll-like receptor 8 (TLR8) agonist, one of several compounds under investigation as part of Gilead's HBV cure program. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy ® (tenofovir alafenamide fumarate, TAF). Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum. US regulators have approved Gilead's Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus (HCV) both with . Gilead is working with regional partners to introduce branded Sovaldi®, Harvoni® and Epclusa . Gilead targets hep B in half a billion dollar deal with Precision BioSciences Biopharma looks to genome editing platform to discover hepatitis B cure Following its success in curing hepatitis C with therapies such as Sovaldi and Harvoni, Gilead is now enlisting a new partner in the fight against hepatitis B (HBV). based Gilead Sciences was developing its hepatitis C treatment, Sovaldi, the medical community was wowed by the 90% cure rate the drug . Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease. "Gilead's cure-based approach to hepatitis B is comprehensive and exciting," said Precision's chief scientific officer, Derek Jantz. Yet access to these medicines that have proven to be a major breakthrough for the treatment of hepatitis C remains limited in China and many other middle-income countries due to exorbitant pricing. Gilead has a long history of developing therapies for hepatitis, developing drug therapies for hepatitis C virus (HCV) a few years back that have effectively provided a cure for the disease. Centers for Disease Control and Prevention. Anuj Gaggar, VP, Clinical Research, Virology at Gilead, stated, "We believe that selgantolimod. makes the two leading drugs that can quickly cure hepatitis C infections. GlaxoSmithKline (GSK) and Gilead Sciences, Inc. If you test positive for chronic hepatitis B, treatments are available. National Elimination Programs: In 2015, Gilead helped launch the Georgian HCV Elimination Project in partnership with the Georgian government and the U. Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a 'functional . He points out that hepatitis C, initially thought to be incurable, can now be cured with new combination treatments. Study participants who have previously received treatment for HBV may also be given Gilead's Vemlidy (tenofovir alafenamide fumarate, TAF). Gilead has developed today’s leading medicines for viral hepatitis. Bzowej,2 Kyong-Mi Chang,3 Jessica P. Executive Director, Program Strategy Leadership (HBV Cure) Gilead Sciences is continuing to hire for all open roles. Gilead Sciences Inc struck a deal to buy biotechnology company Pharmasset Inc for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments. There is no cure for chronic HBV infections, but recent success in Gilead Sciences is the only company that has a solid presence in HBV . 7 billion deal for a German biotech focused on hepatitis delta virus. Global Hepatitis B Virus Treatment Market 2021 With Industry Top Players (Merck and Co, Gilead Sciences, Novartis AG, GlaxoSmithKline), Growth Factors, Size, Share, Development Strategy, Trends. The lives of 5 million HCV-infected Americans and an estimated 160 million HCV-infected people worldwide are at stake. 15 billion euros, in the company’s latest deal to jump. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B . Research into a functional cure for hepatitis B could make this upstart a big player someday. Please help us continue to offer this kind of essential resource for the treatment of hepatitis B with a donation toward our important programs. This detailed page of information is made possible by the hard work and research performed by the Hepatitis B Foundation. Advocates scandalized that Gilead's hepatitis C profits have raked in US$25. HCV can be easily cured with just 12 weeks of oral direct-acting antiviral (DAA) drugs. Viread ® (tenofovir disoproxil fumarate) and Vemlidy ® (tenofovir alafenamide) are indicated for the treatment of chronic hepatitis B. 12, 2021 8:12 AM ET Gilead Sciences, Inc. At that price, treating the entire infected Egyptian . If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic. 1 Chronic hepatitis B causes almost 40% of cases of hepatocellular carcinoma, which is the second leading cause of cancer-related mortality worldwide. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. It recently announced preclinical trial results in monkeys where a two-drug. Sign in to save Director Clinical Development HBV Cure at Gilead Sciences This is an opportunity to work in a dynamic role to support the clinical development of novel drugs for HBV cure. 2% of the world’s population, are estimated to be living with chronic hepatitis B infection (CHB) [1,2]. Find out the benefits of B vitamins. A functional cure, defined as a sustained hepatitis B surface antigen (HBsAg) loss or seroconversion based on assays with a lower limit of HBsAg detection of 0. After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California. We work with regional business partners and generic licensees to sell Viread and Vemlidy for HBV at discounted prices in more than 140 developing countries. is a research-based bio-pharmaceutical company that discovers, develops and commercializes. Today, there are alternatives manufactured by AbbVie, . It is acquired at birth or later via person-to-person transmission. Gilead will also present clinical and real-world data on global efforts to support the World Health HBV Treatment and Functional Cure. , one of the leaders in HIV drug development, and the company which essentially created a cure for hepatitis C, may be well on its way to developing a cure for HIV. Current treatments suppress HBV replication, but they don't completely clear up the infection. NEW YORK/MUNICH/PARIS, SEPTEMBER 11, 2018—This week in . Up to six new HBV drugs set to launch by 2027. When Roche ( OTCQX:RHHBY) pulled out of an alliance with Inovio (NASDAQ: INO) two weeks ago to develop a hepatitis B treatment, it might. 40%) giant from California entered a definitive agreement to acquire a German drug developer with a recently approved treatment for hepatitis delta virus (HDV). The two companies will work together on a phase 2 trial aimed at finding a functional cure for HBV using different combinations of treatments . Gilead Sciences is pursuing a new avenue toward hepatitis B treatment, collaborating on gene therapies aimed at eliminating viral infections in vivo by using Precision BioSciences’ genome editing p. VEMLIDY is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease. , basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B. “Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection,” . If Approved, Bulevirtide Will Be the First Treatment Option for Adult Patients in the U. Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus - Quick Facts. achieved a scientific breakthrough when it developed a cure for hepatitis C, the viral infection that can have severe . Vaccinations and hepatitis diagnostic tests play a pivotal role in the prevention and early detection of the infection to reduce the spread of disease. Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV). Research Scientist - HBV Cure Gilead Sciences Foster City, CA 2 months ago Be among the first 25 applicants. These results, along with new data from Gilead's HBV cure and hepatitis C (HCV) research programs, are being presented at The Liver Meeting® . Gilead has developed today's leading medicines for viral hepatitis. Gilead's Asegua Therapeutics selected to partner with health. Trainings are designed to teach clinical providers how to screen for and treat hepatitis B and C, to work with special populations who are burdened with high . It is the successor to Gilead's Sovaldi, which has accrued more . Talk to your doctor to see if treatment is right for . announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies to develop a functional cure for the chronic hepatitis B virus. Executive Director, Program Strategy Leadership (HBV Cure) Gilead Sciences Foster City, CA 4 days ago Be among the first 25 applicants. There are three primary types of hepatitis. PRACTICEGUIDELINE AASLD Guidelines for Treatment of Chronic Hepatitis B Norah A. Gilead is working with regional partners to introduce branded Sovaldi ®, Harvoni ® and Epclusa ® in low- and middle-income countries, prioritizing those with the greatest disease burden. Functional cure is defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B Contact: Gilead Clinical Study Information Center . -- Data Demonstrate Reductions in Hepatocellular Carcinoma in Hepatitis B (HBV) Patients Treated with Vemlidy --. A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead's RNA interference project, . is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor Hepcludex ® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV). Back in 2014, Gilead Sciences introduced Sovaldi, the first drug to offer a cure for hepatitis C. achieved a scientific breakthrough when it developed a cure for hepatitis C, the viral infection that can have severe and deadly complications. Three years ago, Gilead Sciences was generating record sales and profits on the back of its hepatitis C pills. Gilead already has vast experience in hepatitis C, producing. Overall, about 600,000 people are estimated to have been cured of hep C in the . 2 The current prophylactic vaccine has no effect on. “Gilead's cure-based approach to hepatitis B is comprehensive and exciting,” said Precision’s chief scientific officer, Derek Jantz. Harvoni, a Hepatitis C Drug From Gilead, Wins FDA Approval. The Benefits of B Vitamins. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy ® (tenofovir alafenamide fumarate, TAF). A viral infection that attacks the liver, it is responsible for more than 800,000 deaths 1 every year. Sovaldi, an expensive Hepatitis C treatment, is made by Gilead Sciences. Gilead Science, the drug maker widely criticized for pricing a life-saving anti-viral drug beyond the reach of many patients, has also used . (RTTNews) - Gilead Sciences, Inc. Gilead and Vir unite to find a ‘functional cure’ for hepatitis B. on developing immunomodulatory therapies to treat chronic hepatitis C virus (HCV) infection. Harvoni, made by Gilead Sciences, has cure rates of between 94 and 99 per cent. Lectured by Sharon Lewin, FRACP, PhD, FAAHMS Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, . Food and Drug Administration ( FDA) for tenofovir alafenamide (TAF) 25 mg, an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection. said Thursday it will acquire Germany’s MYR GmbH and its new hepatitis drug for about $1. The companies’ combined commercialisation activities will expand access to tenofovir for the treatment of HBV, once approved, to patients. “We believe rapid action is needed to prevent and treat hepatitis C virus among persons who inject drugs in Kenya, particularly those . New Pharmacological Approaches to a Functional Cure of Hepatitis B. -- Improved Markers of Bone and Renal Safety Also Seen with Vemlidy in Separate Analysis of HBV Patients with Hepatic or Renal Impairment --. Gilead Sciences of Foster City, California, which makes tenofovir and one of the bestselling hepatitis C cure drugs, has more than 60 scientists aiming to . Gilead Sciences and trendy biotech Vir Biotechnology are teaming up in the effort to find a cure to the liver disease hepatitis B. The uproar has died down a bit and there's now much less debate. An estimated 257 million people around the world live with the hepatitis B virus (HBV). Gilead (GILD) is going after another of the big chronic viral infections Hepatitis B virus (HBV). First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research – FOSTER CITY, Calif. In the crowded race to cure hepatitis C, Gilead Sciences is winning - for now. To view the original version on The Express Wire visit Global Hepatitis B Virus Treatment Market 2021 With Industry Top Players (Merck and Co, Gilead Sciences, Novartis AG, GlaxoSmithKline. Closer than ever, according to Timothy Block, PhD, president and co-founder of the Hepatitis B Foundation and its research arm, the Baruch S. Precision Biosciences’ two-year collaboration with Gilead Sciences to develop new therapies to cure hepatitis B will end in September. Finite, short-duration treatment with a clinically relevant dose of GS-9688 is well tolerated and can induce a sustained antiviral response in WHV-infected woodchucks; the identification of a baseline intrahepatic transcriptional signature associated with response to GS-9688 treatment provides insig …. (VIR) have entered into a clinical collaboration to evaluate therapeutic combination strategies aimed at developing a. Hepatitis B virus (Institute for Molecular Virology - University of Wisconsin-Madison) Gilead Sciences and trendy biotech Vir Biotechnology are teaming up in the effort to find a cure to the liver. Hepatitis B virus (HBV) is a major global public health threat with over 257 million people worldwide chronically infected; over 887 000 deaths are caused by the virus every year. TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of. The push is on to cure hepatitis B, a long. “Hepatitis B is in a similar position,” Block believes. But most patients can't afford the expensive . Gilead Sciences of Foster City, California, which makes tenofovir and one of the bestselling hepatitis C cure drugs, has more than 60 scientists aiming to develop a similar weapon against HBV. Through this program, one of the first of its kind in the world, more than 60,000 people have been screened for HCV and more than 43,000 people.